Serum levels of neurofilament light chain, neuron-specific enolase and S100 calcium-binding protein B during acute bacterial meningitis: a prospective cohort study

2021 ◽  
pp. 1-11
Author(s):  
Mads Hjortdal Grønhøj ◽  
Tobias Sejbaek ◽  
Rasmus Würgler Hansen ◽  
Lykke Larsen ◽  
Morten Dahl ◽  
...  
Keyword(s):  
Cohort Study ◽  
Bacterial Meningitis ◽  
Light Chain ◽  
Calcium Binding ◽  
Neuron Specific Enolase ◽  
Serum Levels ◽  
Acute Bacterial Meningitis ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
S100 Calcium Binding Protein

scholarly journals Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status

2017 ◽  
Vol 3 (4) ◽  
pp. 205521731774309 ◽  
Author(s):  
Mariotto S ◽  
Farinazzo A ◽  
Monaco S ◽  
Gajofatto A ◽  
Zanusso G ◽  
...  
Keyword(s):  
Light Chain ◽  
Malignant Disease ◽  
Serum Levels ◽  
Axonal Damage ◽  
Aquaporin 4 ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Spectrum Disorders ◽  
Multiple Sclerosis Patients ◽  
Demyelinating Disorders

Background Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions, including demyelinating disorders. Objectives We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases with neuromyelitis optica spectrum disorders and related disorders. Methods We analysed AQP4-Ab and MOG-Ab with cell-based assay and NF-L with ultrasensitive electrochemiluminescence immunoassay. Results Median NF-L levels were increased in 25 AQP4-Ab-positive patients (59 pg/ml) as compared with 22 MOG-Ab-positive cases (25 pg/ml), 52 seronegative patients (18 pg/ml), 25 multiple sclerosis patients (12 pg/ml) and 14 healthy controls (12 pg/ml). Conclusions Increased serum levels of NF-L in patients with AQP4-Ab or MOG-Ab might reflect an ongoing axonal damage and a more malignant disease course.

scholarly journals Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study

2019 ◽  
Vol 18 (12) ◽  
pp. 1103-1111 ◽  
Author(s):  
Emma L van der Ende ◽  
Lieke H Meeter ◽  
Jackie M Poos ◽  
Jessica L Panman ◽  
Lize C Jiskoot ◽  
...  
Keyword(s):  
Cohort Study ◽  
Frontotemporal Dementia ◽  
Light Chain ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Multicentre Cohort Study ◽  
Multicentre Cohort

scholarly journals Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury

2020 ◽  
Author(s):  
Elisabet Wentz ◽  
Sandra Rydberg Dobrescu ◽  
Lisa Dinkler ◽  
Carina Gillberg ◽  
Christopher Gillberg ◽  
...  
Keyword(s):  
Anorexia Nervosa ◽  
Single Molecule ◽  
Light Chain ◽  
Axonal Degeneration ◽  
Neuronal Injury ◽  
Serum Levels ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
National Patient ◽  
History Of

Abstract Little is known about the long-term consequences of anorexia nervosa (AN) in terms of possible brain neuronal injury. We aimed at investigating whether women with adolescent-onset AN exhibit increased serum levels of neurofilament light chain protein (NfL), a biomarker for neuronal injury, compared with matched controls at 30-year follow-up. Blood samples were collected from 34 women with adolescent-onset AN and 38 matched healthy comparison women (COMP), at a mean age of 44 years (range 38–48 years). NfL was measured in serum using the in-house single molecule array (Simoa) method. The individuals were asked whether they or their parents had been diagnosed with dementia. The Swedish National Patient Register was searched for diagnoses related to dementia. Serum NfL concentrations were significantly higher in the AN group (AN 27.7 pg/ml; COMP 19.0 pg/ml; p = 0.041). When individuals with medical/neurological disorders in the AN and COMP groups were excluded, there was a statistically non-significant trend towards higher concentrations in the AN group (AN 27.4 pg/ml; COMP 18.8 pg/ml; p = 0.060). None of the participants had been diagnosed with dementia. There was no significant correlation between serum NfL and AN duration (r = 0.15). There was a moderate negative correlation between the serum NfL concentration and the current BMI in the AN group (r = 0.44). This is the first time that serum NfL has been assessed in middle-aged women with a history of adolescent-onset AN. The results suggest that there might be increased axonal degeneration as a sequel of AN. Individuals remaining underweight had higher serum NfL concentrations than those with a normal/high BMI. Additional studies are needed to confirm increased serum NfL concentrations in individuals recovered from AN. There is a need for further study of axonal degeneration as a consequence of AN.

scholarly journals Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

2017 ◽  
Vol 24 (8) ◽  
pp. 1046-1054 ◽  
Author(s):  
Fredrik Piehl ◽  
Ingrid Kockum ◽  
Mohsen Khademi ◽  
Kaj Blennow ◽  
Jan Lycke ◽  
...  
Keyword(s):  
Single Molecule ◽  
Light Chain ◽  
Detection Threshold ◽  
Therapy Response ◽  
Serum Levels ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Post Marketing ◽  
Highly Correlated ◽  
Ms Therapy

Background: Neurofilament light chain (NFL) is a cerebrospinal fluid (CSF) marker of neuroaxonal damage in multiple sclerosis (MS). Objective: To determine the correlation of NFL in CSF and serum/plasma, and in plasma after switching from injectable MS therapies to fingolimod. Methods: A first cohort consisted of MS patients ( n = 39) and neurological disease controls ( n = 27) where CSF and plasma/serum had been collected for diagnostic purposes. A second cohort ( n = 243) consisted of patients from a post-marketing study of fingolimod. NFL was determined with Single Molecule Array (Simoa™) technology (detection threshold 1.95 pg/mL). Results: Mean NFL pg/mL (standard deviation ( SD)) was 341 (267) and 1475 (2358) in CSF and 8.2 (3.58) and 17.0 (16.94) in serum from controls and MS, respectively. CSF/serum and plasma/serum levels were highly correlated ( n  = 66, rho  = 0.672, p  < 0.0001 and n  = 16, rho  = 0.684, p  = 0.009, respectively). In patients starting fingolimod ( n = 243), mean NFL pg/mL ( SD) in plasma was reduced between baseline (20.4 (10.7)) and at 12 months (13.5 (7.3), p < 3 × 10−6), and levels remained stable at 24 months (13.2 (6.2)). Conclusion: NFL in serum and CSF are highly correlated and plasma NFL levels decrease after switching to highly effective MS therapy. Blood NFL measurement can be considered as a biomarker for MS therapy response.

scholarly journals CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis

2021 ◽  
Vol 9 (1) ◽  
pp. e1123
Author(s):  
Nora Chekrouni ◽  
Thijs M. van Soest ◽  
Matthijs C. Brouwer ◽  
Eline A.J. Willemse ◽  
Charlotte E. Teunissen ◽  
...  
Keyword(s):  
Bacterial Meningitis ◽  
Light Chain ◽  
Neuronal Damage ◽  
Area Under The Curve ◽  
Case Fatality ◽  
High Serum ◽  
Unfavorable Outcome ◽  
Index Test ◽  
Neurofilament Light Chain ◽  
Neurofilament Light

Background and ObjectivesNeurofilament light chain (NfL) is a biomarker for neuroaxonal damage and has been found to be elevated proportionally to the degree of neuronal damage in neurologic diseases. The objective of this study was to determine the prognostic accuracy of NfL concentrations on unfavorable outcome in adults with community-acquired bacterial meningitis.MethodsWe measured NfL concentration CSF samples from a prospective cohort study of adults with community-acquired bacterial meningitis in The Netherlands and determined associations between NfL CSF concentrations, clinical characteristics, and outcome in multivariate analyses. We identified independent predictors of an unfavorable outcome (Glasgow Outcome Scale scores 1–4) by logistic regression.ResultsCSF NfL concentrations were evaluated in 429 episodes of 425 patients with community-acquired bacterial meningitis. The median age of 429 episodes was 62 years (interquartile range, 50–69 years). Of note, 290 of 422 (68%) episodes presented with an altered mental status (Glasgow Coma Scale score < 14). Most common causative pathogens were Streptococcus pneumoniae (73%), Neisseria meningitidis (7%), and Listeria monocytogenes (5%). The overall case fatality rate was 62 of 429 (15%), and unfavorable outcome occurred in 57 (37%) of 429 episodes. In multivariate analysis, predictors of unfavorable outcome were older age (OR 1.03, 95% CI 1.01–1.05), cranial nerve palsy (OR 4, 95% CI 1.6–10.3), high serum C-reactive protein concentration (OR 1.3, 95% CI 1.01–1.05), and high CSF NfL concentration (OR 1.5, 95% CI 1.07–2.00). CSF NfL concentrations were higher in patients presenting with focal cerebral deficits (717 pg/mL [416–1,401] vs 412 pg/mL [278–731]; p < 0.001). The area under the curve (AUC) for predicting unfavorable outcome in bacterial meningitis of CSF NfL concentration was 0.69 (95% CI, 0.64–0.74).DiscussionCSF NfL concentration is independently associated with unfavorable outcome in adults with community-acquired bacterial meningitis, suggesting that CSF NfL concentration may be a useful biomarker for prognostic assessment in bacterial meningitis.Classification of EvidenceCan the level of NfL in CSF (the index test) predict unfavorable outcome in patients with bacterial meningitis, in a cohort of bacterial meningitis patients with a favorable and unfavorable outcome? This study provides Class II evidence that NfL level in CSF is a moderate predictor, with the AUC for predicting unfavorable outcome in bacterial meningitis being 0.69 (95% CI, 0.64–0.74).

Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study

2019 ◽  
Vol 26 (9) ◽  
pp. 1200-1204 ◽  
Author(s):  
J. P. Cuello ◽  
M. L. Martínez Ginés ◽  
J. Kuhle ◽  
J. M. García Domínguez ◽  
A. Lozano Ros ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Light Chain ◽  
Prospective Cohort ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Multiple Sclerosis Patients

scholarly journals Neurofilament light chain predicts disease activity in relapsing-remitting MS

2017 ◽  
Vol 5 (1) ◽  
pp. e422 ◽  
Author(s):  
Kristin N. Varhaug ◽  
Christian Barro ◽  
Kjetil Bjørnevik ◽  
Kjell-Morten Myhr ◽  
Øivind Torkildsen ◽  
...  
Keyword(s):  
Disease Activity ◽  
Single Molecule ◽  
Light Chain ◽  
Interferon Beta ◽  
Serum Levels ◽  
Serum Samples ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
T2 Lesions ◽  
Relapsing Remitting

Objective:To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS).Methods:A cohort of 85 patients with RRMS were followed for 2 years (6 months without disease-modifying treatment and 18 months with interferon-beta 1a [IFNB-1a]). Expanded Disability Status Scale was scored at baseline and every 6 months thereafter. MRI was performed at baseline and monthly for 9 months and then at months 12 and 24. Serum samples were collected at baseline and months 3, 6, 12, and 24. We analyzed the serum levels of NF-L using a single-molecule array assay and CHI3L1 by ELISA and estimated the association with clinical and MRI disease activity using mixed-effects models.Results:NF-L levels were significantly higher in patients with new T1 gadolinium-enhancing lesions (37.3 pg/mL, interquartile range [IQR] 25.9–52.4) and new T2 lesions (37.3 pg/mL, IQR 25.1–48.5) compared with those without (28.0 pg/mL, IQR 21.9–36.4, β = 1.258, p < 0.001 and 27.7 pg/mL, IQR 21.8–35.1, β = 1.251, p < 0.001, respectively). NF-L levels were associated with the presence of T1 gadolinium-enhanced lesions up to 2 months before (p < 0.001) and 1 month after (p = 0.009) the time of biomarker measurement. NF-L levels fell after initiation of IFNB-1a treatment (p < 0.001). Changes in CHI3L1 were not associated with clinical or MRI disease activity or interferon-beta 1a treatment.Conclusion:Serum NF-L could be a promising biomarker for subclinical MRI activity and treatment response in RRMS. In clinically stable patients, serum NF-L may offer an alternative to MRI monitoring for subclinical disease activity.ClinicalTrials.gov identifier:NCT00360906.

Sign in / Sign up

Export Citation Format

Share Document